Radiopharm schedules FDA end-of-Phase 2 meeting to align Phase 3 trial design for RAD101 brain metastases imaging agentPUBT·1 day ago, 07:03 AMRADX-1.87%
Radiopharm Theranostics plans Phase 3 registrational trial of imaging agent RAD101 in Q4 2026PUBT·Jul 31 at 06:01 AMRADX-1.87%SHL
Bernstein Sticks to Its Buy Rating for Siemens Healthineers AG (SEMHF)Tip Ranks·Jul 31 at 02:35 AMSHL
Siemens Healthineers Q3 Profit Climbs; Lifts FY26 Earnings View, Cuts Revenue Growth Outlookrttnews·Jul 31 at 12:56 AMSHL
SHL: Strong Imaging and Precision Therapy growth offset Diagnostics weakness; EPS outlook raisedQuartr·Jul 31 at 12:17 AMSHL
Siemens Healthineers Q3 FY26 adjusted EBIT rises 15.6% to €1.1 billion; revenue increases 2.8% to €5.76 billionPUBT·Jul 31 at 12:03 AMSHL
Siemens Healthineers Appoints João Seabra President and Head of the Americas | SMMNY Stock NewsStockTitan·Jul 30 at 04:00 AMSHL
12:00 ETADLM announces 2026 Top Corporate Supporter Award recipients and thanks them for their essential backingprnewswire·Jul 28 at 11:01 AMDHR-1.51%ABT+2.09%
Siemens Healthineers wins CE mark for 24 Atellica capillary blood test claimsPUBT·Jul 27 at 11:02 AMSHL
Siemens Healthineers wins CE mark for 24 Atellica capillary blood testing claimsPUBT·Jul 23 at 07:33 AMSHL
Radiopharm Theranostics partners with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trialPUBT·Jul 22 at 06:00 AMRADX-1.87%SHL
